健脾化瘀方含药血清调控SREBP1/SLC7A11/GPX4轴促进铁死亡抑制胰腺癌PANC-1细胞增殖、侵袭的机制OA
Mechanism of Jianpi Huayu Formula Mediated Serum in Promoting Ferroptosis via the SREBP1/SLC7A11/GPX4 Axis to Inhibit the Proliferation and Invasion of Pancreatic Cancer PANC-1 Cells
目的 基于调控固醇调节元件结合蛋白 1(SREBP1)/溶质载体家族 7 成员 11(SLC7A11)/谷胱甘肽过氧化物酶 4(GPX4)轴促进铁死亡,探讨健脾化瘀方含药血清抑制胰腺癌 PANC-1 细胞增殖、侵袭的机制.方法 将 20 只SD大鼠随机分为给药组、对照组(每组 10 只),分别灌胃健脾化瘀方药液(26.8 g·kg-1·d-1)及生理盐水(每日 1 次,连续 7 d),制备健脾化瘀方含药血清及空白血清.体外培养PANC-1 细胞,采用CCK-8法检测不同浓度(0%、0.5%、2.5%、5%、10%、15%、20%)健脾化瘀方含药血清干预 24 h后的细胞存活率,并选择合适的药物浓度进行后续实验.采用克隆形成实验检测细胞增殖能力;划痕实验检测细胞迁移能力;Transwell实验检测细胞侵袭能力;荧光探针法检测细胞内中性脂质、活性氧(ROS)及脂质过氧化水平;微量法检测细胞亚铁离子(Fe2+)、谷胱甘肽(GSH)、丙二醛(MDA)水平;RT-qPCR 及 Western Blot 法检测细胞SREBP1、SLC7A11、GPX4、N-cadherin、E-cadherin、Vimentin mRNA及蛋白表达水平.结果 (1)与空白对照组比较,2.5%、5%、10%、15%、20%健脾化瘀方含药血清可显著抑制PANC-1 细胞存活率(P<0.05,P<0.01),且呈浓度依赖性;健脾化瘀方含药血清的IC50 值为 15.40%,选取 5%、10%、15%含药血清浓度作为健脾化瘀方低、中、高剂量进行后续实验.(2)与空白对照组比较,健脾化瘀方低、中、高剂量组及吉西他滨(5 μmol·L-1)组PANC-1 细胞的相对克隆形成数、24 h细胞迁移率及侵袭细胞数均显著降低(P<0.05,P<0.01).与空白对照组比较,健脾化瘀方低、中、高剂量组PANC-1 细胞中ROS、Fe2+、MDA水平显著升高(P<0.05,P<0.01),GSH水平显著降低(P<0.01),细胞内脂质过氧化水平显著升高(P<0.05,P<0.01),中性脂质积累显著减少(P<0.05,P<0.01),SREBP1、GPX4、SLC7A11、N-cadherin、Vimentin mRNA及蛋白表达水平显著降低(P<0.05,P<0.01),E-cadherin mRNA 及蛋白表达水平显著升高(P<0.05,P<0.01).结论 健脾化瘀方含药血清可以有效地抑制胰腺癌PANC-1 细胞的增殖、迁移及侵袭,其作用机制可能与抑制SREBP1 表达,减少细胞内脂质累积,诱导胰腺癌细胞铁死亡有关.
Objective To investigate the mechanism by which the medicated serum of Jianpi Huayu Formula(JPHYF)inhibits the proliferation and invasion of pancreatic cancer PANC-1 cells,based on its role in regulating the SREBP1/SLC7A11/GPX4 axis to promote ferroptosis.Methods Twenty SD rats were randomly divided into a control group and a drug-administered group(n=10 per group).These rats were intragastrically administered either JPHYF decoction(26.8 g·kg-1·d-1)or an equal volume of normal saline once daily for 7 consecutive days to prepare JPHYF medicated serum and blank control serum,respectively.PANC-1 cells were cultured in vitro.The CCK-8 assay was used to measure changes in cell viability after 24-hour intervention with different concentrations(0%,0.5%,2.5%,5%,10%,15%,20%)of JPHYF medicated serum,and appropriate concentrations were selected for subsequent experiments.Colony formation assay was employed to detect cell proliferation capacity;scratch wound healing assay was applied to assess cell migration ability;Transwell assay was applied to evaluate cell invasion ability;fluorescent probes were used to measure intracellular neutral lipid content,reactive oxygen species(ROS)levels,and lipid peroxidation levels;micro-methods were applied to detect cellular ferrous iron(Fe2+),glutathione(GSH),and malondialdehyde(MDA)levels;RT-qPCR and Western Blot were performed to determine the mRNA and protein expression levels of SREBP1,SLC7A11,GPX4,N-cadherin,E-cadherin,and Vimentin.Results(1)Compared with the blank control group,JPHYF medicated serum at concentrations of 2.5%,5%,10%,15%,and 20%significantly inhibited the survival rate of PANC-1 cells(P<0.05,P<0.01)in a concentration-dependent manner.The IC50 value of JPHYF medicated serum was 15.40%.Consequently,concentrations of 5%,10%,and 15%medicated serum were selected as the low-,medium-,and high-dose JPHYF groups for subsequent experiments.(2)Compared with the blank control group,the relative colony formation number,24-hour cell migration rate,and number of invasive cells were significantly reduced in the JPHYF low-,medium-,and high-dose groups and the gemcitabine group(5 μmol·L-1)(P<0.05,P<0.01).Compared with the blank control group,the JPHYF low-,medium-,and high-dose groups showed significantly increased ROS,Fe2+,and MDA levels of PANC-1 cells(P<0.05,P<0.01),significantly decreased GSH levels(P<0.01),significantly elevated intracellular lipid peroxidation levels(P<0.05,P<0.01),and significantly reduced neutral lipid accumulation(P<0.05,P<0.01).Furthermore,the mRNA and protein expression levels of SREBP1,GPX4,SLC7A11,N-cadherin,and Vimentin were significantly decreased(P<0.05,P<0.01),while the mRNA and protein expression levels of E-cadherin were significantly increased(P<0.05,P<0.01)in the JPHYF treatment groups.Conclusions JPHYF medicated serum can effectively inhibit the proliferation,migration,and invasion of pancreatic cancer PANC-1 cells.Its mechanism of action may be related to the suppression of SREBP1 expression,reduction of intracellular lipid accumulation,and induction of ferroptosis in pancreatic cancer cells.
陈鑫球;朱小玉;黄翰林;方崇锴;姚瑞伟;罗锐;刘抒伟;钟崇;赵希琳
中医证候重点实验室/广州中医药大学第一临床医学院,广东 广州 510405中医证候重点实验室/广州中医药大学第一临床医学院,广东 广州 510405中医证候重点实验室/广州中医药大学第一临床医学院,广东 广州 510405广州中医药大学科技创新中心,广东 广州 510405中医证候重点实验室/广州中医药大学第一临床医学院,广东 广州 510405中医证候重点实验室/广州中医药大学第一临床医学院,广东 广州 510405中医证候重点实验室/广州中医药大学第一临床医学院,广东 广州 510405中医证候重点实验室/广州中医药大学第一临床医学院,广东 广州 510405广州中医药大学第一附属医院,广东 广州 510405
医药卫生
健脾化瘀方含药血清胰腺癌PANC-1 细胞增殖侵袭SREBP1/SLC7A11/GPX4 轴铁死亡大鼠
Jianpi Huayu Formula medicated serumpancreatic cancerPANC-1 cellsproliferationinvasionSREBP1/SLC7A11/GPX4 axisferroptosisrats
《中药新药与临床药理》 2026 (1)
1-11,11
国家自然科学基金项目(82274526)广东省自然科学基金项目(2023A1515011069)广州中医药大学"双一流"与高水平大学学科后备人才培育项目(A1-2601-22-415-023)中医证候重点实验室科研项目广州中医药大学第一临床医学院"揭榜挂帅"研究生创新能力提升项目(A3-0317-25-110-005).
评论